health π¬ Off-the-shelf CAR T could boost cancer access
A next-generation therapy called allogeneic or off-the-shelf CAR T aims to solve access issues with personalized CAR T treatment. This approach uses healthy donor cells instead of a patient's own, allowing for large batch manufacturing. Initial findings from the ALPHA3 study show nearly 60% of patients treated with cema-cel had no detectable cancer DNA post-treatment. Roughly one-third of screenings happened at community cancer centers, suggesting practical local delivery. This could help treat high-risk DLBCL patients earlier, potentially increasing cure rates. π¬